Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAG3 PET ImmunoPET with 89Zr-DFO-REGN3767 in Advanced Solid Tumors on Cemiplimab ± Chemotherapy
2024-516795-15-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 89Zr-DFO-REGN3767 in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 7 more, sponsored by University Medical Center Groningen. Primary endpoints: Comparison of standardized uptake values in tumor lesions and tumor-to-blood ratios at different time points and different 89Zr-DFO-REGN3767 antibody dose levels, Biodistribution and pharmacokinetics of 89Zr-DFO-REGN3767 and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
89Zr-DFO-REGN3767
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)Cervical Cancer (CC)microsatellite instability-high cancer
Beyond the preview
Go deeper on 2024-516795-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516795-15-00.